Dr Noc

BKjr's dumbass claims about "mercury" in vaccines have been thoroughly disproved, so he has to crash around in search of another scary-sounding thing he can use to terrorize the rubes.

Dr Ben

Some more good nerdy stuff.

My oldest is really good at math, and my fatherly guidance was for him to get into Materials Science or Battery Tech.

He didn't.

And this is how we come to blame our kids for our problems instead of looking to our own bad selves for not taking our own advice.

Or something.

Wild Thoughts

I hate thinking I'm falling into a stream of thought that follows a pattern that may well be valid, but may certainly be just a product of several thousand generations of evolutionary training to look for those patterns, and to assume they're the real deal.

Here's a story of the Chaco Canyon civilization which concludes that high-handed theocratic rulers will become literal cannibals in order to impose their will on the people they rule.

And also maybe too - the leaders ate people thinking they could absorb the essence of their victims so they can extend their own lives as well as the power they hold over their subjects. (Nothing new about that, BTW)

At the end of this piece, try not to think about the grisly possibility that American plutocrats may actually have butchered young children, and eaten parts of them, or used parts of them to concoct some stupidly contrived tonic - or serum - or some goddamned thing.

A Nerdy Thing

AI will never replicate this.

A Nerdy Thing

Today's Nerd Thing

This kinda Star Trek shit makes my head buzz.

OK, so first it makes my head hurt, but that goes away after a bit, and then I get the buzz.

Happy now?

Look, it's good to get a Physics For Dummies explanation, but I'm the guy who struggles with a credit card statement, so all the math and science stuff always ends in "it's wonderment".

I'm just glad to know there are people in the world who are working on it for me.

Thank you, nerds.

A Nerd Thing

From a while ago - not sure if I've posted this before, but it seems pretty important.

It'd be nice if I could count on my government to put my money where it helps, instead of always making sure it goes to parasite billionaires and vampire corporations.

Google AI summary:

As of early 2026, MIT faces significant funding reductions due to federal cuts, particularly with the National Institutes of Health (NIH) slashing support for university research. These cuts, which include a 15% cap on indirect costs, could reduce MIT’s funding by $30–$35 million annually, threatening research into cancer, Alzheimer's, and other diseases.

Key Impacts on MIT Cancer Research:Reduced Funding:

The NIH, under the second Trump administration, has targeted reductions in indirect costs—essential for lab infrastructure, safety, and operational costs.

Impact on Research and Staff:

The funding cuts are disrupting ongoing projects and creating a potential, significant impact on scientific output.

Broader Context:

These cuts are part of a broader federal push to reduce NIH funding by roughly 40% in fiscal year 2026.

Massachusetts Impact:

Massachusetts, which receives the largest share of NIH funding per capita, is seeing major reductions, with around 5,783 projects potentially affected.
Proposed Cuts & Opposition: While the administration has proposed drastic budget cuts to science agencies, some legislative efforts are exploring alternative funding levels.

These reductions pose a risk to the ongoing cancer research, which has been crucial in advancing treatments.

Further Exploration:

Read an in-depth analysis of the impact of these cuts on cancer research from The ASCO Post.

View a detailed report on the federal funding cuts and their impact on research in Massachusetts from STAT.

See a comprehensive overview of the proposed science funding cuts in the second Trump administration from Wikipedia.

The Dipshit Diet

Like practically all of Felon47's cabinet, BKjr is a clear and present danger.

I had this really annoying pain in my left side - kinda down low on my belly - so I Googled it, and found this guy on Reddit (I think he said he's a plumber) who has some great opinions, and snappy comebacks in the comments section, and his cousin's roommate's sister-in-law says what I need is to find the best chiropractor in town and talk to him about how to relieve the tension in my upper back and neck - it'll fix me right up. Cuz those egghead doctors are all just a buncha pill-pushers who make bank by keeping you sick and raking in the cash for a global cabal of Jewish bankers.

C'mon, people, get your Crown Chakra out of your Root Chakra and have a conversation with somebody who actually knows their shit, like - oh I dunno - an actual fuckin' doctor.

Nobody ever went broke

underestimating the taste or intelligence

of the American people

Today's Nerdy Thing

We have to have this kinda thing going on. I don't know if there was much government funding, but it's McGill University in Montreal, so yeah, probably. Canadians are still pretty normal, in that they're willing to do it right, letting the nerds do what they need to do to get us good and useful stuff.

A Fact

We've been looking for life in places other than Earth for over 60 years. If we imagine the Milky Way galaxy as the oceans on our planet, we've searched approximately one 12-ounce glassful.

If we were looking for fish, how many fish would we find in that 12 ounces of sea water?

A Prized Woman

I can't even spell half the shit this woman knows like the back of her hand.

And to think a drugged up roids ranger with a dead worm in his brain has been put in charge of our national health policy.

Stay home, try to eat right, and get some exercise. This ridiculous charade will pass, and we have to be ready for the massive rebuilding effort we'll have to make on the other side of it.

Congratulations to Dr. Mary Brunkow on receiving the 2025 Nobel Prize in Physiology or Medicine this week in Stockholm.

In her acceptance speech on Wednesday, Dr. Brunkow reflected: "As a woman in science I especially want to acknowledge those role models who gave me the courage and incentive to persevere. My hope is that I in turn can be that role model for my own daughters, who are just now launching out into the world, as well as for other young women who are excited about science."

Dr. Brunkow was honored for groundbreaking discoveries concerning peripheral immune tolerance, which prevents our immune system from attacking the body's own tissues. She identified the gene that controls regulatory T cells -- a previously unknown class of immune cells that act as security guards to keep harmful immune responses in check.

The American scientist shared the prize with Fred Ramsdell, also from the United States, and Shimon Sakaguchi from Japan, who made complementary contributions to understanding peripheral immune tolerance. The discoveries have laid the foundation for a new field of research and spurred the development of treatments for autoimmune diseases and cancer. As Olle Kämpe, chair of the Nobel Committee, explained, their research has "been decisive for our understanding of how the immune system functions and why we do not all develop serious autoimmune diseases."

Brunkow received her Ph.D. from Princeton University in 1991 in molecular biology and is currently a senior researcher at the Institute for Systems Biology in Seattle. Her Ph.D. adviser, former Princeton President Shirley M. Tilghman, described her as "incredibly bright" and "bold," noting that as a student, Brunkow was one of the first brave enough to tackle the mysterious H19 gene, which other scientists had dismissed as junk.

Brunkow and Ramsdell conducted their prize-winning research together at Celltech Chiroscience in 2001, when they identified a mutation in the FOXP3 gene in a mouse strain suffering from lethal autoimmunity. They explained why this specific type of mouse was particularly vulnerable to autoimmune diseases and showed that mutations in the human equivalent of this gene cause IPEX syndrome, a serious autoimmune disease. In 2003, Sakaguchi linked their findings to his earlier discovery of regulatory T cells from the 1990s, proving that the FOXP3 gene governs the development of these crucial immune regulators.
Brunkow, who is now the fourteenth woman to have won the Nobel Prize in Physiology or Medicine, described the regulatory T cells as "rare, but powerful, and they're critical for sort of dampening an immune response". She explained that these cells function as a braking system that prevents the body's immune system from tipping over into attacking itself. Their discoveries have led to potential treatments now in clinical trials for autoimmune diseases, cancer, and stem cell transplant complications.

(hat tip: A Mighty Girl)

Women will save us.

All we have to do is

stay the fuck out of their way

and let them do it.

Good News

Not that it's going to get BKjr to budget on his "position", but maybe more people will get the word, and stop being quite so silly.

Of course, news of the positive effects on the human brain probably won't mean much to people who are already pretty demented by their conspiracy fantasies.

Hope a little. Pray a little.

Shingles vaccine may actually slow down dementia, study finds

If these findings are confirmed, “then this would be groundbreaking for dementia,” an expert said.

A common vaccine meant to ward off shingles may be doing something even more extraordinary: protecting the brain.

Earlier this year, researchers reported that the shingles vaccine cuts the risk of developing dementia by 20 percent over a seven-year period.

A large follow-up study has found that shingles vaccination may protect against risks at different stages of dementia — including for people already diagnosed.

The research, published Tuesday in the journal Cell, found that cognitively healthy people who received the vaccine were less likely to develop mild cognitive impairment, an early symptomatic phase before dementia.AI Icon

Crucially, the study suggests that the shingles vaccine — two doses of which are recommended for adults 50 and older or those 19 and older with a weakened immune system — may help people who already have dementia. Those who got the vaccine were almost 30 percent less likely to die of dementia over nine years, suggesting the vaccine may be slowing the progression of the neurodegenerative syndrome.

“It appears to be protective along the spectrum or the trajectory of the disease,” said Anupam Jena, a professor of health care policy at Harvard Medical School and a physician at Massachusetts General Hospital who reviewed the paper.

There are few effective treatments for dementia and no preventive measures outside lifestyle changes.

“These findings are promising because they suggest that something can be done,” said Alberto Ascherio, a professor of epidemiology and nutrition at the Harvard School of Public Health and a professor of medicine at Harvard Medical School. “Obviously, the vaccine was not designed or optimized to prevent dementia, so this is sort of an incidental finding. In some ways, we are being lucky.”

The results have led to cautious excitement among researchers.

If these findings are confirmed, “then this would be groundbreaking for dementia,” said Maxime Taquet, an associate professor at the University of Oxford who has conducted research into shingles vaccination and dementia risk. “I think there’s no other word for it.”

Protection across the dementia spectrum

Research has linked common vaccines, including for shingles, to lower dementia risk.

For these observational studies, there is a “healthy vaccine bias,” said Ascherio, who wasn’t involved in the study. “People who get vaccines tend to be healthier in general than people who don’t” because they may have different health-related behaviors.

Because randomized controlled trials — the gold standard in medical research — aren’t often feasible in the real world, scientists who conducted the research published Tuesday took advantage of a historical quirk in how Wales rolled out its shingles vaccination program in 2013.

Only Welsh adults born on or after Sept. 2, 1933, were eligible for the vaccine. Those born right before were ineligible, meaning the public health policy effectively set up a “natural experiment” comparing two near-identical groups of people who either met the vaccine eligibility cutoff or missed it.

“The question then is: Where do you start with this vaccine during the disease course? And does it have benefits for those who already have the condition?” said Pascal Geldsetzer, an assistant professor of medicine at the Stanford University School of Medicine and a senior author of the research.

The vaccine was not only associated with a 20 percent reduction of dementia diagnoses, but also a 3.1 percent reduction in diagnoses of mild cognitive impairment over nine years.

“It suggests that from a clinical public health perspective, we should be providing this potentially at early stages, maybe on a regular basis,” Geldsetzer said.

There doesn’t seem to be a time when it’s too late in the disease progression to derive benefits, he added.

Dementia, in its final stages, can lead to death.

During the nine-year follow-up period, almost half of the 14,350 individuals who had dementia in the study sample died of dementia, meaning it was recorded as the underlying cause on their death certificate.

“Bad dementia can lead you to aspirate and have respiratory arrest,” said Jena, who wasn’t involved in the study. “Bad dementia can lead you to be unable to care for yourself.”

The shingles vaccine decreased deaths due to dementia by 29.5 percent. Even when looking at all-cause mortality, the shingles vaccine was associated with a 22.7 percent reduction.

These results “suggest that there is a slowing of this degenerative process,” which seems to be “striking good luck that the vaccine designed for something else would slow a degenerative process,” Ascherio said.

The magnitude of the effects is “almost too good to be true,” said Taquet, who wasn’t involved in the study.

“If those effect sizes really pan out in randomized control trials, then this would be perhaps one of the best treatments we’ve had for dementia in a while, which is the reason why we need to be quite cautious with interpretation,” he said. “That’s why we need the randomized control trials, but I think they really provide the strongest possible push for randomized control trials.”

Shingles vaccines today, research tomorrow

There are study limitations that need to be worked out.

For one, the study looked at the older shingles vaccine using a weakened version of the live varicella-zoster herpes virus. That vaccine has been discontinued in the United States, as well as in the European Union and Australia, and has been replaced with the Shingrix vaccine, which is more effective at preventing shingles and may also be associated with a lower risk of dementia.

However, it’s unknown whether the newer vaccine is also associated with a reduced risk for mild cognitive impairment or death due to dementia, researchers said. Despite its strengths, and its being as close to a randomized controlled trial without being one, the study is still correlational and cannot get at causation.

Still, experts unanimously encourage eligible people to get the vaccine, which reduces the reactivation of the varicella-zoster virus. The virus causes chicken pox in childhood and remains dormant in neuron clusters within the spinal cord. When reactivated in adulthood, the varicella-zoster virus manifests as shingles, which is characterized by a burning, painful rash and can sometimes cause lifelong chronic pain conditions or serious complications in a subset of people.

The Centers for Disease Control and Prevention recommends two doses of a shingles vaccine for adults 50 and older or those 19 and older with a weakened immune system. But uptake has been relatively low: In 2022, 34.4 percent of eligible Americans, including those with weakened immune systems, had received at least one dose of a shingles vaccine in their lifetime.

In the meantime, researchers are pushing for randomized controlled trials as well as studies to understand why the vaccine is protective, which can teach us something fundamental about dementia and help develop better treatments.

“It’s very important that we understand what it is that we’re targeting, because it might allow us to design even more precise therapies,” said Taquet, who is considering running these studies.

Geldsetzer is working to raise money for a randomized controlled trial to directly test the older shingles vaccine on dementia risk, which he said should require less investment because it’s known to be safe and have other benefits.

There’s a lot of excitement to work on this from other researchers, he said, but he’s had no luck getting the money.

“They’d be thrilled to do this if there’s the funding to do so,” Geldsetzer said. “Just excitement unfortunately is not enough.”

Today's Nerdy Thing

This is like the opening sequence of a sci-fi movie.

Jane's Self-Obit

It's shouldn't strike us as amazing that we learned a lot about ourselves because of her studies of chimpanzees. That's how it's supposed to work.

Thank you, Dr Jane.

Quote

I am far less interested in the weight and convolutions of Einstein's brain than I am in the near certainty that people of equal talent have lived and died in cotton fields and sweatshops.

--Stephen Jay Gould

Nature Is Metal

Calling Dr Kennedy

Quick - somebody get hold of BKjr and tell him those evil science nerds are trying to inject heavy metals directly into our brains!

Research on reversing Alzheimer’s reveals lithium as potential key

Years of investigation by scientists at Harvard has revealed that lithium is deeply involved in Alzheimer’s disease, a finding that could lead to new treatments.

Seven years of investigation by scientists at Harvard Medical School has revealed that the loss of the metal lithium plays a powerful role in Alzheimer’s disease, a finding that could lead to earlier detection, new treatments and a broader understanding of how the brain ages.

Researchers led by Bruce A. Yankner, a professor of genetics and neurology at Harvard Medical School, reported that they were able to reverse the disease in mice and restore brain function with small amounts of the compound lithium orotate, enough to mimic the metal’s natural level in the brain. Their study appeared Wednesday in the journal Nature.

“The obvious impact is that because lithium orotate is dirt cheap, hopefully we will get rigorous, randomized trials testing this very, very quickly,” said Matt Kaeberlein, former director of the Healthy Aging and Longevity Research Institute at the University of Washington, who did not participate in the study. “And I would say that it will be an embarrassment to the Alzheimer’s clinical community if that doesn’t happen right away.”

Cue the private equity assholes to buy up all the lithium rights - can't have affordable healthcare now can we.

Yankner, who is also the co-director of the Paul F. Glenn Center for Biology of Aging Research at Harvard, said: “I do not recommend that people take lithium at this point, because it has not been validated as a treatment in humans. We always have to be cautious because things can change as you go from mice to humans.” He added that the findings still need to be validated by other labs.

Although there have been recent breakthroughs in the treatment of Alzheimer’s, no medication has succeeded in stopping or reversing the disease that afflicts more than 7 million Americans, a number projected to reach almost 13 million by 2050, according to the Alzheimer’s Association.

Pathology images from the brain of an Alzheimer's mouse model. The images show that when the mice are treated with a very low dose of lithium orotate, it almost completely eradicates the amyloid plaques and the tau tangle-like structures. (Harvard)

Lithium is widely prescribed for patients with bipolar disorder, and previous research indicated that it held potential as an Alzheimer’s treatment and an antiaging medication. A 2017 study in Denmark suggested the presence of lithium in drinking water might be associated with a lower incidence of dementia.

However, the new work is the first to describe the specific roles that lithium plays in the brain, its influence on all of the brain’s major cell types and the effect that its deficiency later in life has on aging.

Results of the study by Yankner’s lab and researchers at Boston Children’s Hospital and the Rush Alzheimer’s Disease Center in Chicago also suggest that measuring lithium levels might help doctors screen people for signs of Alzheimer’s years before the first symptoms begin to appear. Yankner said doctors might be able to measure lithium levels in the cerebrospinal fluid or blood, or through brain imaging.

How our brains use lithium

In a healthy brain, lithium maintains the connections and communication lines that allow neurons to talk with one another. The metal also helps form the myelin that coats and insulates the communication lines and helps microglial cells clear cellular debris that can impede brain function.

“In normal aging mice,” Yankner said, “lithium promotes good memory function. In normal aging humans,” higher lithium levels also correspond to better memory function.

The depletion of lithium in the brain plays a role in most of the deterioration in several mouse models of Alzheimer’s disease.

Loss of lithium accelerates the development of harmful clumps of the protein amyloid beta and tangles of the protein tau that resemble the structures found in people with Alzheimer’s. Amyloid plaques and tau tangles disrupt communication between nerve cells.

The plaques in turn undermine lithium by trapping it, weakening its ability to help the brain function.

Lithium depletion is involved in other destructive processes of Alzheimer’s: decay of brain synapses, damage to the myelin that protects nerve fibers and reduced capacity of microglial cells to break down amyloid plaques.

Lithium’s pervasive role comes despite the fact that our brains contain only a small amount of it. After examining more than 500 human brains from Rush and other brain banks, Yankner’s team discovered the naturally occurring lithium in the brain is 1,000 times less than the lithium provided in medications to treat bipolar disorder.

Li-Huei Tsai, director of the Picower Institute for Learning and Memory at Massachusetts Institute of Technology and who was not involved in the study, called it “very exciting,” especially when many in the field, including her own lab, have focused on genetic risk factors for Alzheimer’s.

“But clearly genetic risk factors are not the only things,” said Tsai, who is also Picower professor of neuroscience. “There are a lot of people walking around carrying these risk genes, but they are not affected by Alzheimer’s disease. I feel this study provides a very important piece of the puzzle.”

Pathways for treatment

Alzheimer’s treatments mostly help to manage symptoms and slow the decline it causes in thinking and functioning. Aducanumab, lecanemab, and donanemab, all lab-made antibodies, bind to the harmful amyloid plaques and help remove them.

Donepezil, rivastigmine and galantamine ― all in the class of medications known as cholinesterase inhibitors ― work by replenishing a chemical messenger called acetylcholine, which is diminished in Alzheimer’s. Acetylcholine plays an important role in memory, muscle movement and attention.

Yankner and his team found that when they gave otherwise healthy mice a reduced-lithium diet, the mice lost brain synapses and began to lose memory. “We found that when we administered lithium orotate to aging mice [that had] started losing their memory, the lithium orotate actually reverted their memory to the young adult, six-month level,” he said.

Lithium orotate helped the mice reduce production of the amyloid plaques and tau tangles, and allowed the microglial cells to remove the plaques much more effectively.

Yankner said one factor that might help lithium orotate reach clinical trials sooner is the small amount of the treatment needed, which could greatly reduce the risk of harmful side effects, such as kidney dysfunction and thyroid toxicity.

Aside from its potential in treating Alzheimer’s, Yankner said lithium orotate might also have implications for the treatment of Parkinson’s disease, an area his lab is investigating.

“That needs to be rigorously examined,” he said. “But we’re looking at a whole slew of disorders.”

Get Ready To Be Amazed

The nerds have spent millennia doing impressive things by taking small steps to get better analogous/mechanical fixes.

Now they're about to take a giant leap forward by going digital.

This could be truly outstanding.

We can only hope we don't let the politicians and the rubes fuck things up to the point where we foreclose on a future that promises real greatness, instead of settling for some phony sloganeering shit that fits on a hat.

Go get 'em, nerds.

Today's Nerds

Elizabeth Lee Hazen                Rachel Fuller Brown

In 1948, two women changed the course of medicine… by mailing each other dirt.

They weren’t famous professors.

They didn’t work in fancy labs.

In fact, Rachel Fuller Brown, a chemist in Albany, and Elizabeth Lee Hazen, a microbiologist in New York City, never even worked in the same room.

But what they did share was persistence, trust, and a common mission — to find a cure hidden in the most overlooked places: the soil beneath our feet.

Elizabeth would collect microbes from dirt samples across the country and mail them to Rachel. Rachel would test them — one by one — for any antifungal properties. Over time, hundreds of tiny vials traveled through the U.S. postal system in what became a groundbreaking long-distance collaboration.

Then, one humble sample from Virginia changed everything.

They discovered nystatin — the first safe and effective antifungal drug for humans.
It treated infections like candidiasis, athlete’s foot, and life-threatening fungal diseases that had no cure until then.

But nystatin did more than heal people.

It also protected ancient manuscripts, paintings, trees, and priceless works of art from fungal decay. It became a silent guardian not just in hospitals — but in museums and libraries too.
And the fortune they could’ve made?

They donated all of it.

With the royalties from their discovery, Brown and Hazen created a fund to support future scientists — especially young ones, just starting out. No headlines. No awards. Just a lasting legacy.

Quackery Update

There's no such thing as "Alternative Medicine".

If a claim or a remedy or a therapy or a product has been thoroughly tested, studied, debated, peer-reviewed, published, and approved, then it's not alternative medicine anymore. It's just medicine.

Everything else is either hypothesis or flat-out quackery.

From a year ago:

5 months ago: